Drug Profile

NI 03

Alternative Names: NI-03

Latest Information Update: 04 Oct 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Stason Pharmaceuticals
Class Anti-inflammatories; Antineoplastics; Antiulcers; Antivirals; Benzene derivatives; Guanidines; Inorganic sulfur compounds; Small molecules
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

30 Dec 2021 Kangen Pharmaceuticals completes a phase I/II trial in Pancreatitis in USA (PO) (NCT02693093)
04 Oct 2019 NI 03 is still in phase I/II trials for Pancreatitis in US (PO)(NCT02693093)
24 Feb 2016 Phase-I/II clinical trials in Pancreatitis in USA (PO) (NCT02693093)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com